NICE Rejects Donanemab: Treatment Cost-Effectiv...

By Staff Writer

June 19, 2025

How cost-effective is donanemab as an Alzheimer’s treatment, and why did NICE reject its routine use on the NHS? In June 2025, NICE concluded that the donanemab Alzheimer’s treatment cost-effectiveness does not justify routine ...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.